Gamma-aminobutyric acid type A receptor alpha-2, alpha-3, and alpha-5 subunits (GABAA receptor α2/α3/α5)

The Gamma-aminobutyric acid type A (GABAA) receptor is a pentameric ligand-gated ion channel that serves as the primary inhibitory neurotransmitter receptor in the mammalian central nervous system (Rudolph & Knoflach, 2011). The α2, α3, and α5 subunits are specific protein components that, when incorporated into the receptor complex, define its localization and pharmacological sensitivity. Receptors containing α2 and α3 subunits are primarily located in the limbic system and the dorsal horn of the spinal cord, where they mediate anxiolytic and antinociceptive (pain-relieving) effects, respectively (Engin et al., 2012). The α5 subunit is highly enriched in the hippocampus and plays a crucial role in tonic inhibition and the regulation of learning and memory (Sieghart, 2006). In drug development, these subtypes are targeted to achieve specific therapeutic outcomes—such as treating anxiety or cognitive deficits—while avoiding the α1-mediated sedative and amnestic side effects common to traditional benzodiazepines (Atack, 2011). Selective modulation of these subunits offers a pathway for precision medicine in neuropsychiatry, addressing conditions like schizophrenia and chronic pain with improved safety profiles (Gilling et al., 2013).

Other names

GABRA2/3/5GABA(A) receptor subunits alpha-2, alpha-3, and alpha-5Benzodiazepine-sensitive GABA receptors (non-alpha1)

Positive allosteric modulation (PAM) of the GABA-induced chloride current for anxiolytic/analgesic effects, or negative allosteric modulation (NAM) for cognitive enhancement.